Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.17)
# 1,187
Out of 5,056 analysts
108
Total ratings
38.24%
Success rate
16.31%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.79 | +186.74% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.84 | +3,486.96% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.33 | +3,533.06% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.64 | +543.94% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.91 | +475.92% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $80.60 | -37.97% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.41 | +1,105.67% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $4.60 | +4,682.61% | 1 | Aug 19, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.52 | +821.05% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $3.37 | +1,888.13% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $14.75 | +191.53% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.12 | +194.12% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.18 | +535.59% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.93 | +281.68% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $11.41 | +84.05% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $5.39 | +605.01% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.66 | +5,960.61% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $5.92 | +744.59% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $6.02 | +1,793.69% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $8.56 | +2,236.45% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $13.76 | +139.91% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $19.73 | +102.74% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.24 | +2,883.87% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.90 | +363.77% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $6.62 | +1,063.14% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.01 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $40.47 | +23.55% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $4.91 | +572.10% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $11.23 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $8.50 | +205.88% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $204.74 | -86.32% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.48 | +18,873.21% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $11.76 | +78.57% | 2 | Jul 12, 2017 |
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.79
Upside: +186.74%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.84
Upside: +3,486.96%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.33
Upside: +3,533.06%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.64
Upside: +543.94%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.91
Upside: +475.92%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $80.60
Upside: -37.97%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.41
Upside: +1,105.67%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $4.60
Upside: +4,682.61%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.52
Upside: +821.05%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $3.37
Upside: +1,888.13%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $14.75
Upside: +191.53%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.12
Upside: +194.12%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.18
Upside: +535.59%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.93
Upside: +281.68%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $11.41
Upside: +84.05%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $5.39
Upside: +605.01%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.66
Upside: +5,960.61%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $5.92
Upside: +744.59%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $6.02
Upside: +1,793.69%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $8.56
Upside: +2,236.45%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $13.76
Upside: +139.91%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $19.73
Upside: +102.74%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.24
Upside: +2,883.87%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.90
Upside: +363.77%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $6.62
Upside: +1,063.14%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.01
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $40.47
Upside: +23.55%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $4.91
Upside: +572.10%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $11.23
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $8.50
Upside: +205.88%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $204.74
Upside: -86.32%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.48
Upside: +18,873.21%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $11.76
Upside: +78.57%